1. A clinician must choose a long-term laxative for an elderly patient with significant renal impairment. She rejects a magnesium-based agent and selects polyethylene glycol (PEG) 3350. Which combination of pharmacological properties best justifies preferring PEG over a magnesium salt in this specific patient?
A) PEG is renally excreted and therefore safe, whereas magnesium is hepatically cleared and accumulates in kidney disease
B) PEG stimulates the myenteric plexus while magnesium acts only osmotically, making PEG more reliable
C) PEG is neither absorbed nor metabolized and causes no significant electrolyte shifts, while magnesium is partially absorbed and accumulates when renal excretion is impaired
D) Both act identically, but PEG has a faster onset that matters more in renal impairment
E) PEG is fermented to short-chain fatty acids that are safe in renal disease, while magnesium is not
ANSWER: C
Rationale:
Option C is correct. The decision integrates two properties. PEG is a high-molecular-weight polymer that is neither absorbed nor metabolized and produces no significant electrolyte shifts at standard doses, so renal function does not change its safety. Magnesium salts act osmotically but magnesium is partially absorbed; when renal excretion is impaired, magnesium accumulates and risks hypermagnesemia. Combining the absorption profiles of the two agents explains why PEG is preferred here.
Option A: Option A is incorrect. PEG is essentially not absorbed and does not rely on renal excretion, and magnesium is not hepatically cleared; the reasoning is reversed.
Option B: Option B is incorrect. PEG acts osmotically rather than by stimulating the myenteric plexus, so the contrast described is inaccurate.
Option D: Option D is incorrect. The agents do not act identically, and onset speed is not the basis for choosing PEG in renal impairment; magnesium accumulation is.
Option E: Option E is incorrect. PEG is not fermented to short-chain fatty acids (that describes lactulose); its safety in renal disease comes from lack of absorption.
2. A patient on chronic opioids has constipation that persists despite scheduled polyethylene glycol and senna. A peripherally acting mu-opioid receptor antagonist (PAMORA) is added with good effect. Which conceptual point best explains why escalating the standard laxatives was unlikely to succeed and the PAMORA was needed?
A) Standard laxatives lose potency over time through tachyphylaxis, whereas PAMORAs do not
B) Opioid-induced constipation is driven by mu-opioid receptor activation in the enteric plexuses, a receptor-mediated cause that osmotic and stimulant laxatives do not address, whereas a PAMORA blocks that mechanism directly
C) Standard laxatives are inactivated by opioids in the gut lumen, so any dose is ineffective
D) PAMORAs add an osmotic load that standard laxatives cannot provide
E) Opioids prevent absorption of oral laxatives, so only injectable PAMORAs can work
ANSWER: B
Rationale:
Option B is correct. Opioid-induced constipation arises from opioid binding to mu-opioid receptors in the myenteric and submucosal plexuses, reducing motility and secretion and increasing sphincter tone. Osmotic and stimulant laxatives do not address this receptor-mediated cause, so escalation often fails; a PAMORA blocks the peripheral mu-opioid receptors directly, targeting the actual mechanism.
Option A: Option A is incorrect. The failure is mechanistic, not tachyphylaxis to laxatives.
Option C: Option C is incorrect. Opioids do not inactivate laxatives in the lumen; the laxatives simply do not target the receptor-mediated cause.
Option D: Option D is incorrect. PAMORAs work by antagonizing mu-opioid receptors, not by adding an osmotic load.
Option E: Option E is incorrect. Opioids do not block laxative absorption, and PAMORAs include effective oral agents, so the injectable-only claim is wrong.
3. A patient on high-dose opioids for cancer pain has a central nervous system (CNS) tumor with known blood-brain barrier disruption. A PAMORA is being considered for opioid-induced constipation. Conceptually, why does this patient warrant extra caution, and what should prompt discontinuation?
A) Blood-brain barrier disruption inactivates the PAMORA, so a higher dose is needed
B) The tumor increases opioid analgesia, so the PAMORA will have no effect
C) Blood-brain barrier disruption reduces gut receptor density, eliminating PAMORA benefit
D) Disruption of the blood-brain barrier can increase central nervous system exposure to the PAMORA, raising the risk of precipitating opioid withdrawal, and signs of withdrawal should prompt discontinuation
E) PAMORAs always cross the blood-brain barrier regardless of its integrity, so the tumor is irrelevant
ANSWER: D
Rationale:
Option D is correct. PAMORAs achieve peripheral selectivity by being largely excluded from the central nervous system at an intact blood-brain barrier. When the barrier is disrupted (CNS tumor, meningitis, prior radiation) or opioid doses are very high, more drug may reach central receptors, raising the risk of precipitating opioid withdrawal; signs of withdrawal should prompt discontinuation.
Option A: Option A is incorrect. Barrier disruption does not inactivate the drug or require a higher dose; it increases central exposure.
Option B: Option B is incorrect. The tumor does not increase analgesia or abolish the PAMORA effect.
Option C: Option C is incorrect. Barrier disruption does not reduce gut receptor density; the concern is central, not peripheral.
Option E: Option E is incorrect. PAMORAs are normally excluded from the central nervous system, which is precisely why barrier integrity matters here.
4. A traveler returns with several days of diarrhea that now contains visible blood and is accompanied by a fever of 39 degrees Celsius. He asks for loperamide to control the symptoms before a long flight. Applying the principles of antidiarrheal selection, why should loperamide be withheld here?
A) The dysenteric features (blood and high fever) suggest an invasive pathogen, where suppressing propulsive motility can impair pathogen clearance and risk complications such as toxic megacolon
B) Loperamide is ineffective for any diarrhea accompanied by fever
C) Loperamide would accelerate transit and worsen the bloody diarrhea
D) Loperamide is contraindicated only in children, so the concern does not apply to an adult traveler
E) Loperamide cannot be combined with oral rehydration solution, which this patient requires
ANSWER: A
Rationale:
Option A is correct. Blood in the stool with high fever points to an invasive or dysenteric process. In that setting, propulsive motility helps clear the pathogen, and suppressing it with loperamide can prolong illness and risk complications including toxic megacolon. The dysenteric presentation, not the symptom severity alone, is what makes loperamide inappropriate.
Option B: Option B is incorrect. Loperamide is not simply ineffective whenever fever is present; the issue is the danger of motility suppression with invasive disease.
Option C: Option C is incorrect. Loperamide slows transit; it does not accelerate it.
Option D: Option D is incorrect. The contraindication in invasive diarrhea applies to adults as well, not only children.
Option E: Option E is incorrect. Oral rehydration solution can be used alongside antidiarrheals; the reason to withhold loperamide is the invasive presentation.
5. A patient with Clostridioides difficile infection (CDI) has a white blood cell count of 18,000 cells/mcL and a serum creatinine of 1.8 mg/dL. Integrating the CDI severity classification with agent selection, which oral regimen is the most appropriate initial choice?
A) Metronidazole, because it is first-line for all CDI severities
B) Loperamide plus oral rehydration to control symptoms
C) Bezlotoxumab as monotherapy to neutralize toxin
D) Fidaxomicin, because its lower recurrence makes it preferred for severe disease
E) Oral vancomycin, because the laboratory values meet severe CDI criteria, where vancomycin is preferred
ANSWER: E
Rationale:
Option E is correct. A white blood cell count of 15,000 or higher or a serum creatinine of 1.5 mg/dL or higher defines severe CDI. This patient meets both criteria, and oral vancomycin is preferred over fidaxomicin for severe disease based on available data, with 125 mg four times daily as a standard regimen.
Option A: Option A is incorrect. Metronidazole has been downgraded and is no longer first-line for any CDI severity.
Option B: Option B is incorrect. Loperamide is contraindicated in CDI because of toxic megacolon risk and does not treat the infection.
Option C: Option C is incorrect. Bezlotoxumab prevents recurrence and is given with antibiotics; it is not a standalone treatment for active CDI.
Option D: Option D is incorrect. Although fidaxomicin lowers recurrence in non-severe disease, vancomycin is preferred when severe criteria are met.
6. A clinician notes that fidaxomicin's advantage over vancomycin in preventing recurrence appears to disappear when a patient is infected with a hypervirulent NAP1 (ribotype 027) strain. Conceptually, how does the proposed mechanism of fidaxomicin's recurrence advantage relate to this observation?
A) Fidaxomicin is bacteriostatic against 027 strains and bactericidal against others, explaining the difference
B) The recurrence advantage is attributed to fidaxomicin's narrow spectrum sparing colonization-resistance flora such as Bacteroides; this protective effect does not translate into reduced recurrence for hypervirulent 027 strains
C) Vancomycin reaches higher stool concentrations only against 027 strains, neutralizing the advantage
D) Fidaxomicin is systemically absorbed against 027 strains, reducing its colonic effect
E) The 027 strain inactivates fidaxomicin by producing binary toxin
ANSWER: B
Rationale:
Option B is correct. Fidaxomicin's lower recurrence is attributed to its narrow spectrum, which spares Bacteroides and other colonization-resistance organisms that vancomycin suppresses. This advantage is observed for non-hypervirulent strains but is not seen with hypervirulent NAP1/ribotype 027 strains, for reasons that remain incompletely understood; the link is the colonization-resistance mechanism, which does not yield the same benefit against 027.
Option A: Option A is incorrect. The difference is not explained by a switch between bacteriostatic and bactericidal action by strain.
Option C: Option C is incorrect. Vancomycin does not selectively reach higher stool concentrations against 027 strains.
Option D: Option D is incorrect. Fidaxomicin remains minimally absorbed; it is not systemically absorbed against 027 strains.
Option E: Option E is incorrect. Binary toxin contributes to virulence but does not chemically inactivate fidaxomicin.
7. A patient with irritable bowel syndrome with constipation (IBS-C) has both hard stools and prominent abdominal pain. The clinician chooses linaclotide rather than simply increasing an osmotic laxative. Integrating linaclotide's mechanism, why is it particularly well suited to this presentation?
A) Linaclotide is systemically absorbed and provides central analgesia in addition to a laxative effect
B) Linaclotide slows colonic transit, which relieves both constipation and pain
C) By activating guanylate cyclase-C, linaclotide raises cyclic guanosine monophosphate (cGMP), which drives CFTR-mediated fluid secretion and also directly inhibits submucosal pain-sensing neurons, addressing both the constipation and the pain
D) Linaclotide blocks 5-hydroxytryptamine type 3 (5-HT3) receptors, reducing both pain and motility
E) Linaclotide binds bile acids, relieving constipation and reducing visceral pain
ANSWER: C
Rationale:
Option C is correct. Linaclotide activates guanylate cyclase-C, raising intracellular cyclic guanosine monophosphate (cGMP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) to drive chloride and bicarbonate secretion, relieving constipation, and the same cGMP signal directly inhibits submucosal pain-sensing neurons, addressing the abdominal pain. This dual action is why a GC-C agonist suits a patient with both hard stools and pain better than a pure osmotic agent.
Option A: Option A is incorrect. Linaclotide has negligible systemic absorption; its analgesic effect is local, not central.
Option B: Option B is incorrect. Linaclotide increases secretion and transit rather than slowing it.
Option D: Option D is incorrect. 5-HT3 receptor blockade describes alosetron, not linaclotide.
Option E: Option E is incorrect. Bile acid binding describes cholestyramine, not linaclotide.
8. A 45-year-old woman with diarrhea-predominant irritable bowel syndrome (IBS-D) and a prior cholecystectomy is being evaluated for eluxadoline. Reasoning from the drug's mechanism, what is the principal danger of using it in this patient, and why does her surgical history matter?
A) Loss of the gallbladder removes its regulation of bile flow, and eluxadoline's mu-opioid agonism at the sphincter of Oddi can then cause sphincter spasm and acute pancreatitis
B) Without a gallbladder she cannot absorb eluxadoline, so it will be ineffective and another agent is needed
C) The cholecystectomy increases systemic eluxadoline absorption to toxic levels
D) Eluxadoline's delta-opioid antagonism is amplified after cholecystectomy, worsening her diarrhea
E) Cholecystectomy lowers the seizure threshold, and eluxadoline is proconvulsant
ANSWER: A
Rationale:
Option A is correct. Eluxadoline is a mu-opioid receptor agonist (with kappa agonism and delta antagonism) acting largely in the enteric nervous system. After cholecystectomy, the gallbladder no longer regulates bile flow, and unopposed mu-opioid agonism at the sphincter of Oddi can produce sphincter spasm leading to acute pancreatitis. This is why eluxadoline is contraindicated in patients without a gallbladder, illustrating how anatomical variation changes a drug's safety profile.
Option B: Option B is incorrect. The danger is sphincter of Oddi spasm and pancreatitis, not failed absorption; eluxadoline is minimally absorbed regardless.
Option C: Option C is incorrect. The contraindication is not driven by increased systemic absorption to toxic levels.
Option D: Option D is incorrect. The hazard is mu-opioid-mediated sphincter spasm, not amplified delta antagonism worsening diarrhea.
Option E: Option E is incorrect. Eluxadoline is not proconvulsant, and cholecystectomy does not lower the seizure threshold.
9. A patient stable on naloxegol for opioid-induced constipation is found to be taking ketoconazole that was prescribed elsewhere. Integrating naloxegol's metabolism with this new information, what is the best assessment of the situation and the appropriate response?
A) Ketoconazole induces naloxegol metabolism, so the naloxegol dose should be increased to maintain effect
B) The two drugs have no clinically relevant interaction, so both can continue unchanged
C) Ketoconazole and naloxegol compete for renal excretion, so fluids should be increased
D) Ketoconazole is a strong CYP3A4 inhibitor and naloxegol is a CYP3A4 substrate, so co-administration is contraindicated because naloxegol exposure rises and central effects, including opioid withdrawal, become more likely
E) Ketoconazole chelates naloxegol in the gut, so the doses simply need to be separated by two hours
ANSWER: D
Rationale:
Option D is correct. Naloxegol is metabolized by CYP3A4. Ketoconazole is a strong CYP3A4 inhibitor, which markedly raises naloxegol plasma concentrations and increases the risk of central nervous system exposure and opioid withdrawal; the combination is contraindicated. The correct response is to avoid co-administration rather than adjust timing or fluids.
Option A: Option A is incorrect. Ketoconazole inhibits rather than induces CYP3A4, so naloxegol levels rise; increasing the dose would worsen the risk.
Option B: Option B is incorrect. This is a clinically important, contraindicated interaction, not a negligible one.
Option C: Option C is incorrect. The interaction is hepatic CYP3A4 inhibition, not competition for renal excretion.
Option E: Option E is incorrect. The mechanism is metabolic inhibition, not gut chelation, so dose separation does not address it.
10. Two patients are discussed. Patient 1 has had three separate recurrences of Clostridioides difficile infection (CDI) despite appropriate antibiotic courses. Patient 2 is being treated for a first CDI episode but is 80 years old and immunocompromised, placing him at high recurrence risk. Applying recurrence-prevention principles, which approach best matches each patient?
A) Both patients should receive fecal microbiota transplant (FMT) immediately, as it is first-line for any recurrence risk
B) Patient 1 should receive bezlotoxumab and Patient 2 should receive FMT
C) Patient 1 is a candidate for FMT to restore colonization resistance after multiple recurrences, while Patient 2 is a candidate for bezlotoxumab added to his antibiotic course to reduce first-recurrence risk
D) Both patients should receive bezlotoxumab as monotherapy without antibiotics
E) Neither approach is appropriate; only repeated metronidazole courses are indicated
ANSWER: C
Rationale:
Option C is correct. FMT restores a diverse microbiome and colonization resistance and is preferred for multiply recurrent CDI, matching Patient 1. Bezlotoxumab, a toxin B-neutralizing antibody given during an antibiotic course, reduces recurrence risk and gives the greatest absolute benefit in high-risk patients such as the elderly and immunocompromised, matching Patient 2.
Option A: Option A is incorrect. FMT is reserved for recurrent CDI, not used immediately for a first episode regardless of risk.
Option B: Option B is incorrect. The assignments are reversed; FMT fits the multiply recurrent patient and bezlotoxumab fits the high-risk first episode.
Option D: Option D is incorrect. Bezlotoxumab is given with standard-of-care antibiotics, not as monotherapy.
Option E: Option E is incorrect. Metronidazole has been downgraded and repeated courses are not the appropriate recurrence-prevention strategy.
11. A clinician selects a low-dose tricyclic antidepressant (TCA) as a neuromodulator for a patient with diarrhea-predominant irritable bowel syndrome (IBS-D) and pain, but would lean toward a selective serotonin reuptake inhibitor (SSRI) for a different patient with constipation-predominant IBS (IBS-C). Integrating the mechanisms, what best explains this subtype-based preference?
A) TCAs and SSRIs both slow transit, so the choice is based only on cost
B) Low-dose TCAs reduce visceral hypersensitivity and also slow GI transit through anticholinergic effects, which is advantageous in IBS-D, whereas SSRIs tend to accelerate transit, better matching IBS-C
C) TCAs accelerate transit while SSRIs slow it, so the assignments shown are based on that contrast
D) Both agents work only at full antidepressant doses, so subtype does not influence selection
E) TCAs act by blocking guanylate cyclase-C, which is why they suit IBS-D
ANSWER: B
Rationale:
Option B is correct. Low-dose TCAs reduce visceral afferent signaling and enhance descending pain inhibition, addressing visceral hypersensitivity, and their anticholinergic transit-slowing effect is a useful side benefit in IBS-D. SSRIs tend to accelerate GI transit, which makes them better suited to IBS-C. Integrating the transit effects of each class explains the subtype-based preference.
Option A: Option A is incorrect. The two classes differ in their transit effects, so the choice is mechanistic, not purely cost-based.
Option C: Option C is incorrect. The transit effects are reversed in this option; TCAs slow transit and SSRIs accelerate it.
Option D: Option D is incorrect. The analgesic benefit of TCAs appears at low doses, and subtype does influence selection.
Option E: Option E is incorrect. TCAs do not act by blocking guanylate cyclase-C; they modulate visceral pain pathways.
12. A patient with bile acid diarrhea after terminal ileal resection is started on cholestyramine and reports good control of the diarrhea. Two weeks later her levothyroxine appears subtherapeutic and her warfarin effect is erratic. Integrating cholestyramine's mechanism with this new problem, what is the best explanation and corrective step?
A) Cholestyramine is systemically absorbed and induces hepatic metabolism of both drugs, so their doses must be doubled
B) The diarrhea itself is reducing absorption of both drugs, so cholestyramine should be stopped
C) Cholestyramine raises gastric pH, degrading both drugs, so an acid suppressant should be added
D) Cholestyramine competes with both drugs for renal excretion, so fluids should be increased
E) Cholestyramine binds co-administered drugs such as levothyroxine and warfarin in the gut lumen, so other medications should be taken at least 1 to 2 hours before or 4 hours after cholestyramine
ANSWER: E
Rationale:
Option E is correct. Cholestyramine is a non-absorbed anion-exchange resin that binds bile acids but also binds many co-administered drugs in the lumen, including levothyroxine and warfarin, reducing their absorption. The corrective step is to separate dosing, taking other medications at least 1 to 2 hours before or 4 hours after cholestyramine, rather than stopping the effective therapy.
Option A: Option A is incorrect. Cholestyramine is not absorbed and does not induce hepatic metabolism; it binds drugs in the lumen.
Option B: Option B is incorrect. The diarrhea is controlled, and the problem is luminal binding of the co-medications, addressed by dose separation rather than stopping cholestyramine.
Option C: Option C is incorrect. Cholestyramine does not work by raising gastric pH, and an acid suppressant would not solve luminal binding.
Option D: Option D is incorrect. The interaction is luminal binding, not competition for renal excretion.
13. A parent asks whether bismuth subsalicylate is appropriate for a 9-year-old recovering from a viral illness, and separately whether it is safe for the child's grandfather, who takes warfarin. Integrating the two components of the drug, which response best applies its pharmacology to both questions?
A) Although the bismuth component has antimicrobial activity, the systemically absorbed salicylate makes it inappropriate for the child during a viral illness because of Reye syndrome risk and a concern in the grandfather because of a salicylate-warfarin interaction
B) It is safe for both, because the salicylate component is not systemically absorbed
C) It is unsafe for both only because the bismuth ion is toxic to children and to patients on warfarin
D) It is safe for the child but unsafe for the grandfather, because Reye syndrome affects only adults
E) It is unsafe only because the black discoloration of stool could mask gastrointestinal bleeding in both
ANSWER: A
Rationale:
Option A is correct. Bismuth subsalicylate has two relevant components. The bismuth ion provides antimicrobial and toxin-binding activity, but the salicylate moiety is systemically absorbed and represents a meaningful salicylate dose. That salicylate is why it should be avoided in children and teenagers with viral illness (Reye syndrome risk) and why it interacts with anticoagulants such as warfarin. Integrating both components addresses both questions.
Option B: Option B is incorrect. The salicylate component is systemically absorbed, which is the basis for both cautions.
Option C: Option C is incorrect. The cautions stem from the salicylate moiety, not bismuth toxicity.
Option D: Option D is incorrect. Reye syndrome risk is the concern in children, not adults, so the reasoning is reversed.
Option E: Option E is incorrect. Black discoloration is a harmless cosmetic effect and is not the principal safety basis for these two concerns.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.